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Neurodegeneration resultsfromabnormalitiesincerebral metabolismandenergybalancewithinneurons,astrocytes, microglia,or
microvascularendothelialcells ofthe blood-brain barrier. In Alzheimer’s disease, β-amyloidis considered the primary contributor
to neuropathology and neurodegeneration. It now is believed that certain systemic diseases, such as diabetes mellitus, can
contribute to neurodegeneration through the eﬀects of chronic hyperglycemia/insulin resistance resulting in protein glycation,
oxidative stress and inﬂammationwithin susceptible brain regions. Here, we present an overview of research focusing on the role
of protein glycation, oxidative stress, and inﬂammation in the neurodegenerative process. Of special interest in this paper is the
eﬀect of methylglyoxal (MGO), a cytotoxic byproduct of glucose metabolism, elevated in neurodegenerative disease, and diabetes
mellitus, on cerebral protein function and oxidative stress. How MGO interacts with amino acid residues within β-amyloid, and
small peptides within the brain, is also discussed in terms of the aﬀect on protein function.
1.Introduction
Approximately24million peopleworldwide suﬀertheeﬀects
of some form of dementia, with numbers expected to
increase substantially over the next several decades [1].
Neurodegenerative diseases are highly dynamic, multifac-
torial pathological conditions the causes of which remain
poorly understood. The chronic nature of their development
and progression suggests an insidious etiology that may
involve multiple synergistic interactions among biochemi-
cally unrelated molecular species, and perhaps dysfunctional
or overcompensatory metabolic, and immunologic path-
ways. Numerous studies have contributed to our improved,
yet far from completeunderstanding of theetiological causes
ofAlzheimer’sdisease(AD),multiplesclerosis,Pick’sdisease,
Creutzfeldt-Jakob disease (CJD), and Parkinson’s disease
(PD). Many of these studies suggest several mechanistic sim-
ilarities among these clinically disparate diseases, including
abnormalities in protein folding and aggregation, elevated
release of intracellular reactive oxygen species (ROS) leading
to development of oxidative stress and inﬂammation, and
increased glycation of key cellular proteins [2]. In this
paper we will address key elements of our current level
of understanding as they relate to the eﬀects of oxidative
stress and inﬂammation on neuronal degeneration. We will
then focus on the abnormal glycation of proteins and small
peptides relevant to speciﬁc neurodegenerative diseases and
how the formation of aldehydic molecular species, such as
the α-dicarbonyls methylglyoxal (MGO) and glyoxal (GO),
contribute to the chronic development of this process. MGO
is the most reactive dicarbonyl and in vivo during aerobic
glycolysis is formed by the spontaneous decomposition of
triose phosphate intermediates, although MGO can also
form from the oxidative degradation of pentoses, ascorbate,
and lipids [3]. Finally, we will discuss the mechanisms
by which certain proteins and peptides prove susceptible
to nonenzymatic glycation (Maillard reaction) through
interaction of these dicarbonyls with speciﬁc amino acid
residues of their primary structure. This paper is intended
to be a succinct overview of current concepts regarding the
role of protein glycation in the development of oxidative
stress and inﬂammatory response within the CNS. Perhaps2 Journal of Amino Acids
concurrently, posttranslational modiﬁcation of proteins can
also occur via oxidative and lipoperoxidative reaction with
susceptible amino acids. These reactions, together with
glycoxidationlikelycontributebyvarying degreetoneurode-
generation associated with AD and CJD [4, 5].
2.NeurodegenerativeDiseases-Etiological
Similarities
Neurodegenerative disorders of the central nervous system
are slowly developing, insidious conditions that contribute
to initial neuronal cell degeneration and ultimately cell
death. Noteworthy is the occurrence of speciﬁc pathological
markers that denote the major neurodegenerative diseases,
including AD, PD, and CJD. While the cytological location
and expression of these posttranslational pathological mark-
ers may vary each of these disorders involves (1) abnormal
protein folding and aggregation and (2) elevated levels
of nonenzymatic protein glycation. Dicarbonyl molecular
species (MGO and GO) are unavoidable byproductsof sugar
metabolism and are known contributors to the misfolding,
aggregation, and insolubility of susceptible proteins through
their ability to adduct and form crosslinks via stable
advancedglycationendproducts(AGEs)[6,7].UsingPrP27-
30 an infective variant of prion protein (PrPC) isolated from
infected Syrian hamster brain [8], Panza et al. [9]s h o w e din
vitro that AGE formation by GO and MGO is more highly
adducted in noninfectious PrP than in infectious PrP27-30.
Interestingly, theyfound AGE-modiﬁcation ofprionresulted
in reduced ﬁbril formation, an event that may actually
contribute to reduced prion infectivity in vivo.I no t h e r
neurodegenerative diseases, such as AD the eﬀect of AGE-
related adduct formation may contribute to modiﬁcation of
both intracellular (lipofuscin, neuroﬁbrillary tangles; NFTs)
and extracellular proteins (β-amyloid) [10–12]. In addition
to their eﬀects on protein folding and aggregation AGEs are
likely contributors to the generation of ROS and nitrogen
oxygen species, including the radicals superoxide and per-
oxynitrite in AD and other neurodegenerative diseases [13].
Superoxide (O
￿−
2 ) not only can react with nitric oxide (NO
￿)
to form the reactive nonradical peroxynitrite (ONOO−),
but also in the presence of transition metals (e.g., Fe2+),
and Fenton chemistry produces the nonradical hydrogen
peroxide (H2O2) that decomposes to the hydroxyl anion




A well-established hallmark of Alzheimer’s neuropathology
is the excessive presence of extracellular senile plaques,
comprised predominantly of β-amyloid and NFT [16].
Previous study has shown that the glycation process results
in the extracellular formation of adducts and AGEs on
β-amyloid [17], that MGO is a major glycating agent in
this process [18], and that an accelerated polymerization
of the peptide occurs as a result of AGE crosslinkage [19].
These ﬁndings have led to the proposal that AGEs may
act to promote increased β-amyloid and plaque deposition
within the AD brain [2]. AGEs also adduct to proteins
intracellularly, including NFT with the level of glycation
increasing with age and severity of AD [20].
In a recent review by M¨ unch and colleagues [2], a
sequence of events has been outlined detailing the involve-
ment of increased production of MGO through accumula-
tion of triose phosphates [21]. Triosephosphate isomerase
(TPI) is an enzyme that interconverts dihydroxyacetone
phosphate (DHAP) and d-glyceraldehyde phosphate [22],
thus limiting the metabolic production of MGO under
physiological conditions [23, 24]. It is the only glycolytic
enzyme that exhibits a functional deﬁciency correlated
with neurodegenerative disease [25]. The deﬁciency in TPI
function results in the accumulation of DHAP that spon-
taneously degrades to MGO [26]. Dysfunctional TPI in AD
appears to result from a β-amyloid-dependent nitrosylation
of tyrosine in TPI as demonstrated in both AD brain and
in mouse brain overexpressing β-amyloid and presenilin 1
[27]. Together with increased levels of unchelated transition
metals (copper and iron) associated with amyloid plaques,
glycated proteins become increasingly oxidized, resulting in
the elevated presence of cytotoxic proteins [2, 28].
3.1. Glycation and the Onset of Oxidative Stress and Inﬂam-
mation in Neurodegeneration. The generation of ROS and
their cytotoxic eﬀects are common to the pathophysiology
of many neurodegenerative disorders. Noteworthy is the
mechanism by which these free radicals and free-radical-
producing substrates, such as H2O2,a r eg e n e r a t e d .E v i d e n c e
for the presence of oxidative stress within the AD brain is
substantial [29–32] and is multifactorial, originating from
peroxidation of lipids by aldehydes such as hydroxynonenal
[33], protein and DNA oxidation by carbonylation [34],
and glycation-related reactions [35] suggesting an imbalance
between the abnormal production of free-radical species
and the compromised cellular mechanisms responsible for
their neutralization. The question arises however, as to
whether the onset of oxidative stress is an early feature
of neurodegenerative diseases or an epiphenomenon. The
answer to this question remains equivocal, although there
is considerable evidence to support the involvement of ROS
andoxidativestress intheearlydevelopmentandprogression
of neurodegeneration. In PD, ROS are produced at a higher
rate than that observed in age-matched healthy controls.
Moreover, appearance of ROS occurs in association with the
presence of AGEs in Lewy bodies prior to appearance of the
Parkinson’s phenotype [36].
The well-characterized nonenzymatic reaction of reduc-
ing sugars glucose, fructose and glyceraldehyde with sus-
ceptible amino acid residues of proteins can lead to the
irreversible formation of the Schiﬀ base, and the more stable
Amadori product [37]. The reaction may proceed further by
condensation, dehydration, and additional rearrangements
to form advanced glycation endproducts or AGEs [38].
In addition to the potential contribution of β-amyloid to
protein oxidation and oxidative stress [39] experimental
evidence supports the underlying involvement of accelerated
AGEformation asa signiﬁcant contributortooxidativestressJournal of Amino Acids 3
and neurodegeneration of the Alzheimer’s type [40], not
only by the direct production of ROS but also through their
binding to the multiligand receptor RAGE, a cell-surface
molecule and member of the immunoglobulin superfamily
[41,42].Inbothinvitro andinvivostudiesKoandcolleagues
[43] show that AGEs up-regulated the expression of APP, a
response thatcouldbe preventedbythepretreatment ofneu-
roblastoma cells (cell line SH-SY5Y) with the ROS inhibitor
N-acetyl-L-cysteine. Furthermore, the accumulation of β-
amyloid1–42 was also increased following the treatment of
these cells with AGE.
The reciprocal interaction between oxidative stress,
through protein oxidation and lipid peroxidation, and the
activation of proinﬂammatory pathways as part of the innate
immune response within the brain has been extensively
studiedandshown tobeabiologicallysigniﬁcantcomponent
ofneuropathogenesis in AD[43, 44]. This was demonstrated
histochemically in AD brain, where activated microglial
cells and astrocytes, both resident immune cells of the
brain [45], express proinﬂammatory cytokines, including
interleukin (IL)-1β, IL-6, and tumor necrosis factor-α,
along with ROS [46]. This expression of proinﬂammatory
cytokines may result from the binding of β-amyloid1–42
ﬁbrils to complement factor C1q and serum amyloid P
component, as shown by Eikelenboom et al. [47]i nc u l t u r e s
of human microglial cells. The AGE-RAGE pathway is a
signiﬁcant contributor to this process in part through the
ability of RAGE to bind with various proinﬂammatory
ligands, including AGEs and β-amyloid and through the
generation of ROS as second messengers [48]. This was
demonstrated by Gasic-Milenkovic et al. [49]w h os h o w e d
the inﬂammatory response from murine microglial cells was
augmentedbyexposuretoAGE-boundβ-amyloid, relativeto
unbound β-amyloid. Neuroinﬂammation and impairment
of neurogenesis in AD may be promoted not only by β-
amyloid, but also by the intracellular domain of expressed
amyloid precursor protein (AICD), as shown by Ghosal et
al. [50] in transgenic mice coexpressing the 59-residue long
AICD fragment and in APP-knockout mice.
3.2. MGO Cytotoxicity and Neurodegeneration. MGO is the
most reactive α-dicarbonyl and is increased in normal
aging and especially in neurodegenerative disease [51].
Exposure of neuroblastoma cells to MGO for up to 24 hrs
induces depolarization of the plasma membrane, release
of glutamate, and formation of ROS [52]. Experimental
evidence also conﬁrms the capability of MGO to impair
cellular glucose metabolism and energy depletion, as shown
in cultured neuroblastoma cells [53]. Elevated MGO in Type
2 diabetes and in at least some neurodegenerative diseases,
including AD strongly supports the proposal that dicarbonyl
stress, particularly that due toMGO contributessigniﬁcantly
to alterations in protein function in these conditions and to
their neuropathology. Support for this proposal comes from
experiments on cultured rat hippocampal neuronal cells
exposed to MGO [54].MGOinducedoxidative-stress related
neuronal cell death and concurrently induced expression of
nerve growth factor and release of proinﬂammatory cytokine
IL-1β. Studiesalsodemonstrate theabilityofMGO toinhibit
protein function. Argpyrimidine, formed by the reaction of
MGO with arginine residues, is a speciﬁc marker for protein
glycation and is present in human renal tissue and lens
proteins from diabetic patients, as well as in at least some
neurodegenerative conditions [55–57]. These results lend
additional support for a central role of dicarbonyl molecular
speciesinvivo,especiallyMGO,intheearlydevelopmentand
progression of oxidative stress and inﬂammation in diabetes
and neurodegenerative disease.
4.Diabetes Mellitus—ARiskFactorforAD?
Considerable evidence is presented in the literature sup-
porting the association of the 2 major components of Type
2 diabetes mellitus, insulin resistance and hyperglycemia
with dementia of the Alzheimer’s type [58, 59], although
acceptance of this association is not universal. An often
referenced longitudinal study supporting an association is
the Rotterdam study reported by Ott et al. [60]. Study data
gathered from 5,000 subjects 55 years of age and older sug-
gested a strong correlation between Type 2 diabetes and the
subsequent development of AD. Baker et al. [61], reporting
on a study of human subjects diagnosed with diabetes or
presenting with elevated glycemic indices showed that indi-
viduals with increased insulin resistance also presented with
anAD-likepatternofreducedcerebralglucosemetabolicrate
in frontal, parietotemporal, a n dc i n g u l a t e dr e g i o n so ft h e
brain, suggesting insulin resistance as a predictive marker for
AD. Additional support for Type 2 diabetes as a risk factor
for AD comesfrom studies by Curb et al. [62]a n dL e i b s o ne t
al. [63], among others. In view of recent reports, a causative
association between Type 2 diabetes, perhaps as a result
of hyperinsulinemia and/or hyperglycemia, and cognitive
impairment is strong, with an association to AD somewhat
lessso.Althoughbothdiseasesexhibitsomesimilarities, such
as insulin resistance [64], dysregulation of iron homeostasis,
andincreasesinmetallothioneinandhemeoxygenase-1[65],
there is limited evidence that Type 1 or Type 2 diabetes leads
to AD neuropathology [66].
Overall, study ﬁndings to date suggest a strong cor-
relation between chronic Type 2 diabetes and subsequent
development of dementia, however, the eﬀect of diabetes
on cerebral function may be related more to an initial
predisposition to vascular dementia than to development
of classical AD neuropathology [67, 68]. In the following
section we will discuss the involvement of insulin resistance
and hyperglycemia, both hallmarks of Type 2 diabetes in the
pathophysiology of neurodegeneration, including AD.
5.Diabetes MellitusType2 and
Neurodegeneration
Although some question remains as to the predisposition of
the diabetic brain to develop AD pathology, recent studies
suggest a strong correlation between Type 2 diabetes, brain
atrophy and reduced neuronal integrity. In one clinical study
[69] of 89 patients with diabetes, 70 to 82 years of age
MRI scans and cognitive function testing was conducted at
baseline and again 3 years later. After correcting for age,4 Journal of Amino Acids
gender, educational level, hypertension, and treatment with
pravastatin linear regression analysis revealed statistically
signiﬁcant atrophy of the brain in diabetic patients in
comparison to matched control subjects without diabetes. A
second MRI study by de Bresser et al. [70] conducted over 4
years on 55 patients with Type 2 diabetes showed signiﬁcant
reduction in total brain volume and increased peripheral
cerebrospinal ﬂuid volume, leading to the conclusion that
Type 2 diabetes can lead to slow, chronic cerebral atrophy.
Encephalopathy with neuronal degeneration and inﬂamma-
tion has also been demonstrated in the hippocampus of
the streptozotocin (STZ) Type 2 diabetic rat model [71].
The hyperglycemia associated with Type 2 diabetes also
appears to impair gap junctional communication between
astrocytes as shown in (1) cultured astrocytes harvested
from 1-day-old Wistar-Hanover rats and exposed to high
glucose, and (2) brain slices from 20-to-24-week-old STZ
rats [72]. Assessment of gap junction channel-mediated dye
transfer was used to determine astrocytic gap junctional
function.
Diﬃculty in determining the causative relationship
between Type 2 diabetes and AD is, in part, due to
the heterogeneous nature of AD. A deﬁnitive diagnosis
of AD can only be made postmortem. Moreover, AD is
frequently associated with a microvascular component [73],
and as Luchsinger and Gustafson correctly state [74], AD
may illustrate a neurodegenerative disease with a graded
overlapping of vascular and amyloid neuropathologies.
The AD brain exhibits regional glucose hypometabolism
as well as abnormalities in insulin signaling [75], both com-
ponentsofdiabetesmellitus[76,77].The presenceofglucose
hypometabolism and development of a hyperglycemic cel-
lular microenvironment precipitated by progressive insulin
resistance and altered insulin signaling pathways contribute
to neuronal death [78]. MGO may promote neuronal cell
death by contributing directly to insulin resistance via
accelerationofAGE formation [79], and also by involvement
in the combinedeﬀectsof dicarbonyl reactivity with tau, and
hyperphosphorylation of tau and other proteins by protein
O-glycosylation via monosaccharide β-N-acetylglucosamine
attachment to serine/threonine residues via an O-linked
glycosidic bond [80]. Present data suggests that glucose
hypometabolism and insulin resistance in AD contribute to
the development of tau hyperphosphorylation by reduction
of this glycosylation process, thus leading to the formation
of tangles and eventual neuronal cell death [81]. Increased
tau phosphorylation has also been described in a mouse
model of Type 1 (STZ injected) and 2 (db/db) diabetes
mellitus [82]. In this study, tau phosphorylation was found
to increase in the cortex and hippocampus of both mouse
models, but the increase was particularly noteworthy in
the STZ-injected mouse brain. Study results suggested that
tau phosphorylation was directly induced by hyperglycemic
(Type 2) and insulin deﬁciency (Type 1). Similar results
were reported by Ke et al. [83] in the pR5 transgenic mouse
model of AD with superimposition of Type 2 diabetes
induced by STZ. Immunocytochemical and Western blot
analyses indicated tauhyperphosphorylation was accelerated
in the diabetic transgenic model. Hyperglycemic conditions
inType2diabetesandperhaps inADcanelevatetissuedicar-
bonyl levels,primarily MGO and GO molecularspecies, thus
contributing to tau crosslinking and oligomer formation.
That this can occurhas been shown by Kuhla et al. [84], who
demonstrated increased dimer and oligomer formation in
wild-type and pseudophosphorylated mutant tau proteins,




Production of α-dicarbonyl molecular species, most notably
GO and MGO, occursslowly underphysiological conditions,
yet adduction to susceptible lysine, arginine and cysteine
residues occurs, with the hydroimidazolones being the most
commonly formed adducts, primarily on proteins with
long half-lives [85, 86]. Compromise of protein function
is eﬀected initially by glycation of the lysine side chain
and N-terminal amino acid residues, followed by later stage
modiﬁcation involving not only these, but arginine and
cysteineresiduesandstabilizationtoAGEsviaSchiﬀbaseand
Amadori rearrangement [87, 88].The impact ofglycationon
protein function depends in part on the turnover rate of the
protein, and cellular defense mechanisms, such as activity
of the glyoxalase system responsible for the degradation of
unadducted dicarbonyl [89]. Because activity of the glyox-
alase system declineswith progression of Type 2 diabetesand
AD[84]MGOlevelscanrise signiﬁcantly.Glyoxalaseactivity
depends on the availability of reduced glutathione which can
be decreased in neurodegenerative disease [90].
Both in vitro and in vivo studies indicate that presence
of glycating agents, such as MGO, within the vicinity of
arginine, lysine, and cysteine residues of a protein is not
necessarily predictive of adduction at these sites. Moreover,
glycation and reactivity of dicarbonyls with amino acids
is a dynamic process. Jia et al. [91]d e m o n s t r a t e din vitro
the susceptibility of insulin to glycation by MGO, while
glucagon, a protein of similar mass with two arginines and
a single lysine, was resistant to modiﬁcation. Additional
support for the selective nonenzymatic glycation of proteins
comes from studies of human [92], mouse, and rat [93]
plasma proteins obtained from aged populations. Both
studies show glycation may be limited to relatively few
proteins.
The tertiary structure of a protein, and therefore acces-
sibility of the glycating agent to susceptible residues, is a
primary determinant of whether the glycation process pro-
ceeds. This was shown by Gao and Wang [94]who correlated
selective modiﬁcation of speciﬁc arginine residues within
the hemoglobin molecule with solvent accessibility, as deter-
mined by the “relative surface exposable area” calculated for
each arginine within the native molecule. Conversely, in an
earlier study on glycation of RNase protein Watkins et al.
[95] note that the only common characteristic of unreactive
l y s i n er e s i d u e si nt h ep r o t e i nw e r et h e i rl o c a t i o no nt h e
protein surface, and thus readily solvent accessible. They
point out, however, that this nonreactivity may be due toJournal of Amino Acids 5
a calculated 20% reduction in the rate constant for glycation
followingreaction ofhighlyreactivelysineresidues.Asecond
determinant of site speciﬁcity of protein glycation is the
pKA of the competing residues, with the residue having the
lower value more susceptible to initial Schiﬀ base formation
and subsequent conversion to stable glucosamines via the
Amadori rearrangement [96].However, the initial formation
of the Schiﬀ base is not necessarily predictive of the Amadori
rearrangement, as shown by the observation that Lys-41
in bovine pancreatic RNase A although less susceptible to
Schiﬀ b a s em o d i ﬁ c a t i o nt h a ni sNα-lys-1, accounts for more
than twice the Amadori adduct to the RNase. It should
be emphasized that failure of the amino acid to initially
react with the glycating agent does not preclude eventual
modiﬁcation. Thirdly, reactivity with glucose appears to be
enhanced when speciﬁc residues, like lysine, are proximal
to high-aﬃnity binding sites for phosphate ion or organic
phosphate often within basic regions of the molecule, a
frequentconditionwithinsubstrateandeﬀectorbindingsites
of the protein [95]. Proximity of lysine to carboxylic acid
containing residues within the primary or tertiary structure
has been noted by Shapiro et al. [97].
7.Discussionand Summary
The preponderance of reported studies support an associ-
ation between hyperglycemia and insulin resistance/hyper-
insulinemia, both components of uncontrolled Type 2
diabetes,andsimilarconditionsinAD.Increasedglycationof
susceptible proteinsis also of pathophysiological signiﬁcance
in both diabetes and neurodegenerative diseases. Attempting
to demonstrate Type 2 diabetes as a risk factor for AD has
been inherently diﬃcult for 2 reasons: (1) the percentage
of study subjects maintaining good glycemic control has
often not been strictly recorded, thus these individuals may
present with few, if any systemic complications such as
cardiovascular, renal, or peripheral nerve pathology most
often associated with diabetes and (2) conﬁrmation of AD
cannot be made until postmortem examination of brain
sections. To date, there are no reported study ﬁndings
relating the level of long-term glycemic control to cognitive
function in Type 2 diabetes. However, in 2007, Williamson
et al. [98] initiated the Action to Control Cardiovascu-
lar Risk in Diabetes Memory in Type 2 Diabetes Study
(ACCORD-MIND), the ﬁrst such study to formally assess
cognitive outcome following a treatment program designed
to compare the eﬀects of standard care versus intensive care
guidelines. This study should contribute importantly to our
understanding of how, and whether long-term stability of
blood sugar aﬀects cognitive function.
The role of protein and peptide glycation, and that
of MGO and other dicarbonyl molecular species, in the
development and progression of neurodegenerative diseases
remains poorly deﬁned, due largely to a lack of rigorous
corroborative studys conducted in vivo. Interpretation of in
vitro ﬁndings are often tentative, given that tissue localiza-
tion, concentration, half-life, and reactivity of key reactants,
that is, dicarbonyl molecular species, susceptible protein,
and host defense systems, such as antioxidants, reduced
glutathione, and glyoxylase I and 2 may not be reﬂective of
disease conditions in vivo. Nonetheless, there is considerable
evidence supporting the role of protein glycation and
associated oxidative stress and inﬂammation as central to
the progression of some neurodegenerative diseases, AD
being a prime example [99]. However, whether these events
are early, causative events in the disease remains unclear,
although Smith etal. [99] point outthat the presence ofAGE
epitopes localized to diﬀuse β-amyloid plaques represent
an early pathological event in AD. Oxidative stress brought
about by glycation of amino acids, and the irreversible
f o r m a t i o no fA G E si sl i k e l yt ob eb u to n eo fs e v e r a lp a t h w a y s
contributing to protein dysfunction. Recently, elevation of
redox-active iron was found in the cerebral cortex and
cerebellum in human preclinical AD brains, and brains with
mild cognitive impairment (MCI), indicating transition-
metal-induced free radical generation within these brain
regions [100]. Occurrence of increased iron in brain from
MCI patients is also highly suggestive of an iron-generated
free radical-induced primary event within this and perhaps
other neurodegenerative diseases that may respond to the
use of antioxidant therapies. Elevated levels of transition
metals within AD brain may be primary contributors to the
augmentation ofoxidative stress associated with amino acid-
MGO adduct formation. Concurrently, MGO-induced AGE
formation and AGE-RAGE binding can regulate expression
of proinﬂammatory cytokines via redox-sensitive pathways
that may be central to neuroinﬂammation in AD [44].
Potential therapies for AD and other neurodegenerative
diseases focusing on antioxidants, anti-inﬂammatory agents,
and inhibitors of AGE-RAGE pathways are currently intense
areas of research.
In recent years an increasing number of animal models
have been developed that closely approximate conditions
reﬂecting the human disease. Increased emphasis on uti-
lization of these in vivo models in long-term studies of
dicarbonyl-protein interactions is a plausible and necessary
alternative for future investigations. Increased focus on in
vivo studies will be required to determine, conclusively,
the relative involvement of dicarbonyl-induced glycation,
oxidative stress, and inﬂammatory responses in the etiology
of human neurodegenerative disease.
Acknowledgment
This paper is dedicated to Mark A. Smith, Ph.D., a visionary,
whose scientiﬁc passion and curiosity will not be forgotten.
References
[1] A. Kern and C. Behl, “The unsolved relationship of brain
aging and late-onset Alzheimer disease,” Biochimica et Bio-
physica Acta, vol. 1790, no. 10, pp. 1124–1132, 2009.
[2] G. M¨ unch, B. Westcott, T. Menini, and A. Gugliucci,
“Advanced glycation endproducts and their pathogenic roles
in neurological disorders,” Amino Acids. 2010.
[3] T. P. Degenhardt, S. R. Thorpe, and J. W. Baynes, “Chemical
modiﬁcation of proteins by methylglyoxal,” Cellular and
Molecular Biology, vol. 44, no. 7, pp. 1139–1145, 1998.6 Journal of Amino Acids
[4] R. Pamplona, E. Dalfo, V. Ayala et al., “Proteins in human
brain cortex are modiﬁed by oxidation, glycoxidation, and
lipoxidation: eﬀects of Alzheimer disease and identiﬁcation
of lipoxidation targets,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .
280, no. 22, pp. 21522–21530, 2005.
[5] R. Pamplona,A. Naudi, R. Gavin et al., “Increased oxidation,
glycoxidation, and lipoxidation of brain proteins in prion
disease,” Free Radical Biology and Medicine, vol.45, no.8, pp.
1159–1166, 2008.
[6] C.R. HarringtonandC. A.L.S.Colaco,“Alzheimer’s disease.
A glycation connection,” Nature, vol. 370, no. 6487, pp. 247–
248, 1994.
[7] A.Gafni,“Structuralmodiﬁcationsofproteinsduringaging,”
Journal of the American Geriatrics Society,v o l .4 5 ,n o .7 ,p p .
871–880, 1997.
[ 8 ] S .B .P r u s i n e r ,M .P .M c K i n l e y ,K .A .B o w m a ne ta l . ,“ S c r a p i e
prions aggregate to form amyloid-like birefringent rods,”
Cell, vol. 35, no. 2, pp. 349–358, 1983.
[9] G. Panza, C. Dumpitak, and E. Birkmann, “Inﬂuence of the
maillardreaction to prionprotein aggregation,”Rejuvenation
Research, vol. 13, no. 2-3, pp. 220–223, 2010.
[10] K. Horie, T. Miyata, T. Yasuda et al., “Immunohistochemical
localization of advanced glycation end products, pentosi-
dine, and carboxymethyllysine in lipofuscin pigments of
Alzheimer’s disease and aged neurons,” Biochemical and
Biophysical Research Communications, vol. 236, no. 2, pp.
327–332, 1997.
[11] S.D.Yan,X.Chen,A.M.Schmidtetal.,“Glycatedtauprotein
in Alzheimer disease: a mechanism for induction of oxidant
stress,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica, vol.91,no.16,pp.7787–7791,1994.
[12] M.A.Smith,S.Taneda,P.L.Richeyetal.,“Advanced Maillard
reaction end products are associated with Alzheimer disease
pathology,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 91, no. 12, pp. 5710–5714,
1994.
[13] C. Loske, A. Neumann, A. M. Cunningham et al., “Cyto-
toxicity of advanced glycation endproducts is mediated by
oxidative stress,” J o u r n a lo fN e u r a lT r a n s m i s s i o n , vol. 105, no.
8-9, pp. 1005–1015, 1998.
[14] R. Carubelli, J. E. Schneider, Q. N. Pye, and R. A. Floyd,
“Cytotoxic eﬀects of autoxidative glycation,” Free Radical
Biology and Medicine, vol. 18, no. 2, pp. 265–269, 1995.
[15] B. J. Ortwerth, H. James, G. Simpson, and M. Linetsky,
“The generation of superoxide anions in glycation reactions
with sugars, osones, and 3-deoxyosones,” Biochemical and
Biophysical Research Communications, vol. 245, no. 1, pp.
161–165, 1998.
[16] J. L. Cummings, H. V. Vinters, G. M. Cole, and Z. S. Khacha-
turian, “Alzheimer’s disease: etiologies, pathophysiology,
cognitive reserve, and treatment opportunities,” Neurology,
vol. 51, no. 1, pp. S2–S17, 1998.
[ 1 7 ]K .C h e n ,J .M a l e y ,a n dP .H .Y u ,“ P o t e n t i a li m p l i c a t i o n so f
endogenous aldehydes in β-amyloid misfolding, oligomer-
ization and ﬁbrillogenesis,” Journal of Neurochemistry,v o l .
99, no. 5, pp. 1413–1424, 2006.
[18] J. Webster, C. Urban, K. Berbaum et al., “The carbonyl scav-
engers aminoguanidine and tenilsetam protect against the
neurotoxic eﬀects of methylglyoxal,” Neurotoxicity Research,
vol. 7, no. 1-2, pp. 95–101, 2005.
[19] C. Loske, A. Gerdemann, W. Schepl et al., “Transition
metal-mediated glycoxidation accelerates cross-linking of β-
amyloid peptide,” European Journal of Biochemistry, vol. 267,
no. 13, pp. 4171–4178, 2000.
[20] H. J. L¨ uth, V. Ogunlade, B. Kuhla et al., “Age- and stage-
dependent accumulationofadvanced glycationend products
in intracellular deposits in normal and Alzheimer’s disease
brains,” Cerebral Cortex, vol. 15, no. 2, pp. 211–220, 2005.
[21] S. A. Phillips and P. J. Thornalley, “The formation of
methylglyoxal from triose phosphates. Investigation using
a speciﬁc assay for methylglyoxal,” European Journal of
Biochemistry, vol. 212, no. 1, pp. 101–105, 1993.
[22] K. K. Desai and B. G. Miller, “A metabolic bypass of the
triosephosphate isomerase reaction,” Biochemistry, vol. 47,
no. 31, pp. 7983–7985, 2008.
[23] J.P.Richard,“Kineticparametersfortheeliminationreaction
catalyzed by triosephosphate isomeraseand an estimation of
the reaction’s physiological signiﬁcance,” Biochemistry,v o l .
30, no. 18, pp. 4581–4585, 1991.
[24] J.P.Richard, “Mechanismfortheformationofmethylglyoxal
fromtriosephosphates,”BiochemicalSocietyTransactions,v ol.
21, no. 2, pp. 549–553, 1993.
[25] S. W. Eber, A. Pekrun, A. Bardosi et al., “Triosephosphate
isomerase deﬁciency: haemolytic anaemia, myopathy with
altered mitochondria and mental retardation due to a new
variant with accelerated enzyme catabolism and diminished
speciﬁc activity,” European Journal of Pediatrics, vol. 150, no.
11, pp. 761–766, 1991.
[26] N. Ahmed, S. Battah, N. Karachalias et al., “Increased
formation of methylglyoxal and protein glycation, oxidation
and nitrosation in triosephosphate isomerase deﬁciency,”
Biochimica et Biophysica Acta, vol. 1639, no. 2, pp. 121–132,
2003.
[27] F. X. Guix, G. Ill-Raga, R. Bravo et al., “Amyloid-dependent
triosephosphate isomerase nitrotyrosination induces glyca-
tion and tau ﬁbrillation,” Brain, vol. 132, no. 5, pp. 1335–
1345, 2009.
[28] H. V. Miranda and T. F. Outeiro, “The sour side of
neurodegenerative disorders:the eﬀects ofproteinglycation,”
Journal of Pathology, vol. 221, no. 1, pp. 13–25, 2010.
[29] N. Durany, G. M¨ u n c h ,T .M i c h e l ,a n dP .R i e d e r e r ,“ I n v e s -
tigations on oxidative stress and therapeutical implications
in dementia,” European Archives of Psychiatry and Clinical
Neuroscience, vol. 249, no. 3, pp. 68–73, 1999.
[30] W. Retz, W. Gsell, G. M¨ u n c h ,M .R o s l e r ,a n dP .R i e d e r e r ,
“Free radicals in Alzheimer’s disease,” Journal of Neural
Transmission, no. 54, pp. 221–236, 1998.
[31] L. M. Sayre, P. I. Moreira, M. A. Smith, and G. Perry, “Metal
ions and oxidative protein modiﬁcation in neurological
disease,” Annali dell’Istituto Superiore di Sanita, vol. 41, no.
2, pp. 143–164, 2005.
[32] L. M. Sayre, G. Perry, and M. A. Smith,“Oxidative stress and
neurotoxicity,” Chemical Research in Toxicology,v o l .2 1 ,n o .
1, pp. 172–188, 2008.
[33] W. R. Markesbery and M. A. Lovell, “Four-hydroxynonenal,
a product of lipid peroxidation, is increased in the brain in
Alzheimer’s disease,” Neurobiology of Aging,v ol.19,no .1,p p .
33–36, 1998.
[34] B. S. Berlett and E. R. Stadtman, “Protein oxidationin aging,
disease, and oxidative stress,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
vol. 272, no. 33, pp. 20313–20316, 1997.
[35] G. M¨ unch, A. M. Cunningham, P. Riederer, and E. Braak,
“Advanced glycationendproducts are associatedwith Hirano
bodies in Alzheimer’s disease,” Brain Research, vol. 796, no.
1-2, pp. 307–310, 1998.
[36] E. Koutsilieri, C. Scheller, E. Gr¨ unblatt, K. Nara, J. Li, and
P. Riederer, “Free radicals in Parkinson’s disease,” Journal of
Neurology, vol. 249, no. 2, pp. 1–5, 2002.Journal of Amino Acids 7
[37] M. Takeuchi and Z. Makita, “Alternative routes for the
formationof immunochemicallydistinct advanced glycation
end-products invivo,”Current Molecular Medicine,v ol.1,no .
3, pp. 305–315, 2001.
[38] M. Brownlee, A. Cerami, and H. Vlassara, “Advanced prod-
ucts of nonenzymatic glycosylation and the pathogenesis of
diabetic vascular disease,” Diabetes/Metabolism Reviews,v o l .
4, no. 5, pp. 437–451, 1988.
[39] R. Sultana, M. Piroddi, F. Galli, and D. A. Butterﬁeld,
“Protein levels and activity of some antioxidant enzymes
in hippocampus of subjects with amnestic mild cognitive
impairment,” Neurochemical Research, vol. 33, no. 12, pp.
2540–2546, 2008.
[40] M. Guglielmotto, L. Giliberto, E. Tamagno, and M. Tabaton,
“Oxidative stress mediates the pathogenic eﬀect of diﬀerent
Alzheimer’s disease risk factors,” Frontiers in Aging Neuro-
science, vol. 2, pp. 1–7, 2010.
[41] M. Neeper, A. M. Schmidt, J. Brett et al., “Cloning and
expression of a cell surface receptor for advanced glyco-
sylation end products of proteins,” Journal of Biological
Chemistry, vol. 267, no. 21, pp. 14998–15004, 1992.
[42] J. Qin, R. Goswami,S. Dawson, and G. Dawson, “Expression
of the receptor for advanced glycation end products in
oligodendrocytes in response to oxidative stress,” Journal of
Neuroscience Research, vol. 86, no. 11, pp. 2414–2422, 2008.
[ 4 3 ]S .Y .K o ,Y .P .L i n ,Y .S .L i n ,a n dS .S .C h a n g ,“ A d v a n c e d
glycation end products enhance amyloid precursor protein
expression by inducing reactive oxygen species,” Free Radical
Biology and Medicine, vol. 49, no. 3, pp. 474–480, 2010.
[44] A.Maczurek,K.Shanmugam,andG.M¨ unch,“Inﬂammation
and the redox-sensitive AGE-RAGE pathway as a therapeutic
target in Alzheimer’s disease,” Annals of the New York
Academy of Sciences, vol. 1126, pp. 147–151, 2008.
[45] S. M. Lucas, N. J. Rothwell, and R. M. Gibson, “The role of
inﬂammation in CNS injury and disease,” British Journal of
Pharmacology, vol. 147, no. 1, pp. S232–S240, 2006.
[ 4 6 ]A .W o n g ,H .J .L ¨ uth, W. Deuther-Conrad et al., “Advanced
glycation endproducts co-localize with inducible nitric oxide
synthasein Alzheimer’s disease,” Brain Research, vol.920, no.
1-2, pp. 32–40, 2001.
[ 4 7 ]P .E i k e l e n b o o m ,R .V e e r h u i s ,A .F a m i l i a n ,J .J .M .H o o z e -
m a n s ,W .A .v a nG o o l ,a n dA .J .M .R o z e m u l l e r ,“ N e u -
roinﬂammation in plaque and vascular β-amyloid disorders:
clinical and therapeutic implications,” Neurodegenerative
Diseases,vol. 5, no. 3-4, pp. 190–193, 2008.
[48] A. Wong, S. Dukic-Stefanovic, J. Gasic-Milenkovic et al.,
“Anti-inﬂammatory antioxidants attenuate the expression of
inducible nitric oxide synthase mediated by advanced glyca-
tion endproducts in murine microglia,” European Journal of
Neuroscience, vol. 14, no. 12, pp. 1961–1967, 2001.
[49] J. Gasic-Milenkovic, S. Dukic-Stefanovic, W. Deuther-
Conrad, U. G¨ artner, and G. M¨ unch, “β-amyloid peptide
potentiates inﬂammatory responses induced by lipopolysac-
charide, interferon -γ and ’advanced glycation endproducts’
in a murine microglia cell line,” European Journal of Neuro-
science, vol. 17, no. 4, pp. 813–821, 2003.
[50] K. Ghosal, A. Stathopoulos,and S. W. Pimplikar, “APP intra-
cellular domain impairs adult neurogenesis in transgenic
miceby inducingneuroinﬂammation,”PLoS ONE,v o l .5 ,n o .
7, Article ID e11866, 2010.
[51] M. A. Grillo and S. Colombatto, “Advanced glycation end-
products (AGEs): involvement in aging and in neurodegen-
erative diseases,” Amino Acids, vol.35, no. 1,pp. 29–36, 2008.
[52] S. Garcia de Arriba, U. Kr¨ ugal, R. Regenthal et al., “Carbonyl
stress and NMDA receptor activation contribute to methyl-
glyoxalneurotoxicity,”Free Radical Biology and Medicine,v ol.
40, no. 5, pp. 779–790, 2006.
[53] S. G. de Arriba, G. Stuchbury, J. Yarin, J. Burnell, C. Loske,
and G. M¨ unch, “Methylglyoxal impairs glucose metabolism
and leads to energy depletion in neuronal cells-protection by
carbonyl scavengers,”NeurobiologyofAging,vol.28,no.7,pp.
1044–1050, 2007.
[54] S. Di Loreto, V. Caracciolo, S. Colafarina, P. Sebastiani,
A. Gasbarri, and F. Amicarelli, “Methylglyoxal induces
oxidative stress-dependent cell injury and up-regulation of
interleukin-1β and nerve growth factor in cultured hip-
pocampalneuronalcells,”BrainResearch,vol.1006,no.2,pp.
157–167, 2004.
[55] A. K. Padival, J.W. Crabb, and R. H. Nagaraj,“Methylglyoxal
modiﬁes heat shock protein 27 in glomerular mesangial
cells,” FEBS Letters, vol. 551, no. 1–3, pp. 113–118, 2003.
[56] T. Oya, N. Hattori, Y. Mizuno et al., “Methylglyoxal
modiﬁcation of protein. Chemical and immunochemical
characterization of methylglyoxal-arginine adducts,” Journal
of Biological Chemistry, vol. 274, no. 26, pp. 18492–18502,
1999.
[57] R. Jabeen, A. A. Mohammad, E. C. Elefano, J. R. Petersen,
and M. Saleemuddin, “Antibodies and Fab fragments protect
Cu,Zn-SOD against methylglyoxal-induced inactivation,”
BiochimicaetBiophysicaActa,vol.1760,no.8,pp.1167–1174,
2006.
[58] C. M. Carlsson, “Type 2 diabetes mellitus, dyslipidemia, and
Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 20,
no. 3, pp. 711–722, 2010.
[59] A. A. Sima, “Encephalopathies: the emerging diabetic com-
plications,” Acta Diabetologica, vol. 47, no. 4, pp. 279–293,
2010.
[60] A.Ott,R.P.Stolk,F.vanHarskamp,H.A.P.Pols,A.Hofman,
and M. M. B. Breteler, “Diabetes mellitus and the risk of
dementia:theRotterdamStudy,” Neurology,v ol.53,no .9,pp .
1937–1942, 1999.
[61] L.D.Baker,D.J.Cross,S.Minoshima,D.Belongia,G.Stennis
Watson, and S. Craft, “Insulin resistance and alzheimer-
like reductions in regional cerebral glucose metabolism for
cognitively normal adults with prediabetes or early type 2
diabetes,” Archives of Neurology, vol. 68, no. 1, pp. 51–57,
2011.
[ 6 2 ] J .D .C u r b ,B .L .R o d r i g u e z ,R .D .A b b o t te ta l . ,“ L o n g i t u d i n a l
association of vascular and Alzheimer’s dementias, diabetes,
andglucosetolerance,”Neurology,vol.52,no.5,pp.971–975,
1999.
[63] C. L. Leibson, W. A. Rocca, V. A. Hanson et al., “The
risk of dementia among persons with diabetes mellitus: a
population-based cohort study,” Annals of the New York
Academy of Sciences, vol. 826, pp. 422–427, 1997.
[64] N.Moroz,M.T ong,L.Longato,H.X u,andS.M.delaMonte,
“LimitedAlzheimer-typeneurodegenerationinexperimental
obesity and type 2 diabetes mellitus,” Journal of Alzheimer’s
Disease, vol. 15, no. 1, pp. 29–44, 2008.
[65] E. Gr¨ unblatt, J. Bartl, and P. Riederer, “The link between
iron, metabolic syndrome, and Alzheimer’s disease,” Journal
of Neural Transmission. 2010.
[66] C. Messier and M. Gagnon, “Cognitive decline associated
with dementia and type 2 diabetes: the interplay of risk
factors,” Diabetologia, vol. 52, no. 12, pp. 2471–2474, 2009.8 Journal of Amino Acids
[67] H. Umegaki, “Pathophysiology of cognitive dysfunction in
older people with type 2 diabetes: vascular changes or
neurodegeneration?” Age and Ageing,vol. 39,no. 1, pp. 8–10,
2010.
[68] A. Verdelho, S. Madureira, C. Moleiro et al., “White matter
changes and diabetes predict cognitive decline in the elderly:
the LADIS Study,” Neurology, vol. 75, no. 2, pp. 160–167,
2010.
[ 6 9 ]S .G .C .v a nE l d e r e n ,A .d eR o o s ,A .J .M .d eC r a e ne t
al., “Progression of brain atrophy and cognitive decline in
diabetes mellitus: a 3-year follow-up,” Neurology, vol. 75, no.
11, pp. 997–1002, 2010.
[70] J. de Bresser, A. M. Tiehuis, E. van den Berg et al., “Progres-
sion of cerebral atrophy and white matter hyperintensities in
patients with type 2 diabetes,” Diabetes Care, vol. 33, no. 6,
pp. 1309–1314, 2010.
[71] S. S. Yi, I. K. Hwang, D. W. Kim et al., “The chronological
characteristics of SOD1 activity and inﬂammatory response
in the hippocampi of STZ-induced type 1 diabetic rats,”
Neurochemical Research, vol. 36, no. 1, pp. 117–128, 2011.
[ 7 2 ]G .K .G a n d h i ,K .K .B a l l ,N .F .C r u z ,a n dG .A .D i e n e l ,
“Hyperglycaemia and diabetes impair gap junctional com-
munication among astrocytes,” ASN Neuro,v o l .2 ,n o .2 ,p p .
57–73, 2010.
[73] J. A. Luchsinger, “Type 2 diabetes, related conditions, in
relation and dementia: an opportunity for prevention?”
Journal of Alzheimer’s Disease, vol. 20, no. 3, pp. 723–736,
2010.
[ 7 4 ]J .A .L u c h s i n g e ra n dD .R .G u s t a f s o n ,“ A d i p o s i t y ,t y p e2
diabetes, and Alzheimer’s disease,” Journal of Alzheimer’s
Disease, vol. 16, no. 4, pp. 693–704, 2009.
[75] E. Steen, B. M. Terry, E. J. Rivera et al., “Impaired insulin
and insulin-like growth factor expression and signaling
mechanisms in Alzheimer’s disease—is this type 3 diabetes?”
Journal of Alzheimer’s Disease,vol. 7, no. 1, pp. 63–80, 2005.
[76] P. Revill, M. A. Moral, and J. R. Prous, “Impaired insulin
signalingand the pathogenesisof Alzheimer’s disease,” Drugs
of Today, vol. 42, no. 12, pp. 785–790, 2006.
[77] L. Mosconi, “Brain glucose metabolism in the early and
speciﬁc diagnosis of Alzheimer’s disease: FDG-PET studies
in MCI and AD,” European Journal of Nuclear Medicine and
Molecular Imaging, vol. 32, no. 4, pp. 486–510, 2005.
[78] M. Brownlee, “Advanced protein glycosylation in diabetes
and aging,” Annual Review of Medicine, vol. 46, pp. 223–234,
1995.
[ 7 9 ] Q .G u o ,T .M o r i ,Y .J i a n ge ta l . ,“ M e t h y l g l y o x a lc o n t r i b u t e st o
the development of insulin resistance and salt sensitivity in
Sprague-Dawley rats,” Journal of Hypertension,v o l .2 7 ,n o .8 ,
pp. 1664–1671, 2009.
[80] F. Liu, K. Iqbal, I. Grundke-Iqbal, G. W. Hart, and C. X.
Gong, “O-GlcNAcylation regulates phosphorylation of tau:
a mechanism involved in Alzheimer’s disease,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 101, no. 29, pp. 10804–10809, 2004.
[81] W. B. Dias and G. W. Hart, “O-GlcNAc modiﬁcation in
diabetes and Alzheimer’s disease,” Molecular BioSystems,v o l .
3, no. 11, pp. 766–772, 2007.
[ 8 2 ]B .K i m ,C .B a c k u s ,S .O h ,J .M .H a y e s ,a n dE .L .F e l d m a n ,
“Increased tau phosphorylation and cleavage in mouse
modelsoftype 1andtype 2diabetes,” Endocrinology,vol.150,
no. 12, pp. 5294–5301, 2009.
[ 8 3 ]Y .D .K e ,F .D e l e r u e ,A .G l a d b a c h ,J .G o t z ,a n dL .M .I t t n e r ,
“Experimental diabetes mellitus exacerbates Tau pathology
in a transgenic mouse model of Alzheimer’s disease,” PLoS
ONE, vol. 4, no. 11, article e7917, 2009.
[ 8 4 ]B .K u h l a ,K .B o e c k ,A .S c h m i d te ta l . ,“ A g e -a n ds t a g e -
dependent glyoxalase I expression and its activity in normal
and Alzheimer’s disease brains,” Neurobiology of Aging,v o l .
28, no. 1, pp. 29–41, 2007.
[85] P.J.Thornalley,“Endogenousα-oxoaldehydes andformation
of protein andnucleotide advanced glycation endproducts in
tissuedamage,”NovartisFoundationSymposium,vol.285,pp.
229–243, 2007.
[86] P. J. Thornalley, A. Langborg, and H. S. Minhas, “Formation
of glyoxal, methylglyoxal and 8-deoxyglucosone in the glyca-
tionofproteins byglucose,”BiochemicalJournal,vol.344,no.
1, pp. 109–116, 1999.
[87] N. Ahmed and P. J. Thornalley, “Advanced glycation end-
products: what is their relevance to diabetic complications?”
Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 233–245,
2007.
[88] J. Zeng and M. J. Davies, “Evidence for the formation of
adducts and S-(carboxymethyl)cysteine on reaction of α-
dicarbonyl compounds with thiol groups on amino acids,
peptides, and proteins,” Chemical Research in Toxicology,v o l .
18, no. 8, pp. 1232–1241, 2005.
[89] A. Negre-Salvayre, R. Salvayre, N. Auge, R. Pamplona, and
M. Portero-Otin, “Hyperglycemia and glycation in diabetic
complications,”Antioxidants and Redox Signaling,v ol.11,no .
12, pp. 3071–3109, 2009.
[90] P. J.Thornalley, “Glutathione-dependent detoxiﬁcation of α-
oxoaldehydes by the glyoxalase system: involvement in dis-
ease mechanisms and antiproliferative activity of glyoxalaseI
inhibitors,” Chemico-Biological Interactions, vol. 111-112, pp.
137–151, 1998.
[91] X. Jia, D. J. Olson, A. R. Ross, and L. Wu, “Structural and
functional changes in human insulin induced by methylgly-
oxal,” FASEB Journal, vol. 20, no. 9, pp. 871–879, 2006.
[92] S. Poggioli, H. Bakala, and B. Friguet, “Age-related increase
of protein glycation in peripheral blood lymphocytes is
restricted to preferential target proteins,” Experimental
Gerontology, vol. 37, no. 10-11, pp. 1207–1215, 2002.
[93] C. K. Jana, N. Das, and R. S. Sohal, “Speciﬁcity of age-
related carbonylation of plasma proteins in the mouse and
rat,” Archives of Biochemistry and Biophysics, vol. 397, no. 2,
pp. 433–439, 2002.
[94] Y. Gao and Y. Wang, “Site-selective modiﬁcations of arginine
residues in human hemoglobin induced by methylglyoxal,”
Biochemistry, vol. 45, no. 51, pp. 15654–15660, 2006.
[95] N. G. Watkins, S. R. Thorpe, and J. W. Baynes, “Glycation
of the amino groups in protein: studies on the speciﬁcity
of modiﬁcation of RNase by glucose,” Journal of Biological
Chemistry, vol. 260, no. 19, pp. 10629–10636, 1985.
[96] D. J. Walton and B. H. Shilton, “Site speciﬁcity of protein
glycation,” Amino Acids, vol. 1, no. 2, pp. 199–203, 1991.
[97] R. Shapiro, M. J. McManus, C. Zalut, and H. F. Bunn, “Sites
of nonenzymatic glycosylation of human hemoglobin A,”
J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 255, no. 7, pp. 3120–
3127, 1980.
[98] J. D. Williamson,M. E. Miller, R. N. Bryan et al.,“The action
to controlcardiovascularrisk in diabetes memoryin diabetes
study (ACCORD-MIND): rationale, design, and methods,”
American Journal of Cardiology, vol. 99, no. 12, pp. S112–
S122, 2007.Journal of Amino Acids 9
[99] M.A .Smit h,L.M.Sa yr e ,V .M.M onnie r ,andG .P e rry ,“ R ad -
ical AGEing in Alzheimer’s disease,” Trends in Neurosciences,
vol. 18, no. 4, pp. 172–176, 1995.
[100] M. A. Smith, X. Zhu, M. Tabaton et al., “Increased iron and
free radical generation in preclinical Alzheimer disease and
mild cognitive impairment,” Journal of Alzheimer’s Disease,
vol. 19, no. 1, pp. 353–372, 2010.